| Paroxysmal nocturnal hemoglobinuria: Where we stand |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Paroxysmal nocturnal hemoglobinuria: Where are we going |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Massive hemolysis in paroxysmal nocturnal hemoglobinuria after switching from proximal complement inhibitor to anti-C5 therapy: A lesson not to be forgotten |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Clinical decision-making and treatment of myelodysplastic syndromes |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| The Importance of Controlling Terminal Complement Activity and Intravascular Hemolysis in Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Iron overload after complement inhibitor treatment of Paroxysmal Nocturnal Hemoglobinuria |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Haploidentical stem cell transplantation (haplo-SCT) represents the main alternative for children with inherited bone marrow failure syndrome (I-BMF) lacking a matched donor. This retrospective study, conducted on behalf of the EBMT SAAWP and PDWP, aims t |
|
American Society of Clinical Oncology Educational Book |
Myelodysplastic Syndromes (MDS) |
| New Approvals in Low- and Intermediate-Risk Myelodysplastic Syndromes |
|
American Society of Clinical Oncology Educational Book |
Myelodysplastic Syndromes (MDS) |
